Nuvectis Pharma, Inc. (NVCT) fair value analysis
Nasdaq · Updated 2026-10-19
NVCT price how computed
Valuation status
No fair-value estimate yetNVCT has no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for our trailing P/E history.
Forward Fair Value needs both, so TickrTrends publishes no verdict for NVCT yet. We re-check every week; the price, fundamentals, technicals and earnings data below are unaffected.
- Last price
- $18.60
- Sector
- Healthcare
- 12-month range
- $5.65–$28.53
- Market cap
- $607M
- From 52-week high
- -34.8%
- Shares outstanding
- 32.6M
- Rank in Healthcare by quality score
- #301 of 301
Last price is the 2026-10-16 close; the chart runs through 2026-10-16.
Nuvectis Pharma, Inc. is a biopharmaceutical company focused on developing therapies for patients with cancer and other serious diseases. The company is headquartered in the United States and operates as a publicly traded entity on the Nasdaq exchange.
NVCT currently ranks #301 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $607M
- P/E (trailing)
- n/m
- EPS (TTM)
- $-1.31
- Shares outstanding
- 32.6M
Derived indicators how computed
- Quality grade
- F
- 52-week position
- The upper-middle quarter of its range
Technicals how computed
- RSI (14-day)
- 41 · neutral
- 50-day average
- $21.61
- 200-day average
- $14.06
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Earnings how computed
- Next earnings report
- 2026-11-03
- Last 8 quarters vs consensus
- 2 beat, 5 missed
- Quarter by quarter
- 2026-06 ▼ miss (-20.0%)
2026-03 ▲ beat (+16.1%)
2025-12 ▬ met (0.0%)
2025-09 ▼ miss (-76.0%)
2025-06 ▼ miss (-20.0%)
2025-03 ▼ miss (-8.0%)
2024-12 ▼ miss (-36.3%)
2024-09 ▲ beat (+4.0%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 5 buy · 0 hold · 0 sell (5 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $35.4
- Target vs last price
- +90.3%
What our data shows for NVCT
- Shares are trading in the middle of their 12-month price range of $5.65–$28.53.
- The 14-day relative strength index sits at a neutral 41.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- NVCT's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the NVCT conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — NVCT's 50/200-day trend state shifted from uptrend to mixed this week, indicating a change in the stock's intermediate momentum trajectory. The healthcare company's derived indicators reflect this transition as the relationship between shorter and longer-term moving averages has become less clearly directional. The stock's valuation verdict remains awaiting full valuation.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — NVCT's 50/200-day trend state shifted from mixed to uptrend this week, according to TickrTrends' derived indicators. The healthcare sector company remains in an uptrend phase based on this technical measure. The current valuation verdict for NVCT is awaiting full valuation.
- 2026-09-28 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is NVCT stock undervalued?
TickrTrends has no fair-value estimate for NVCT yet: there is no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for a trailing P/E history. It is re-checked every week.
What is NVCT's TickrTrends verdict?
NVCT is currently marked 'No fair-value estimate yet' - a verdict publishes automatically once a forward earnings consensus and enough reported quarters are available.
How does NVCT compare to other Healthcare stocks?
NVCT ranks #301 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is NVCT overbought or oversold?
NVCT's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does NVCT report earnings next?
NVCT's next earnings report is scheduled for 2026-11-03, per the published earnings calendar.
Does NVCT usually beat earnings estimates?
Over its last 8 reported quarters NVCT beat the consensus estimate 2 times and missed 5 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about NVCT?
Of 5 analysts covering NVCT, 5 rate it a buy, 0 a hold and 0 a sell - buy-leaning, with a consensus price target of $35.4 (+90.3% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.